What’s new
PRESS RELEASE: Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board
OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has
Health Economics model for OncoProg® commissioned
Oxford Cancer Biomarkers Ltd partners with York Health Economics Consortium to demonstrate OncoProg ®
PRESS RELEASE: OncoProg receives CE mark
Oxford Cancer Biomarkers achieves CE mark for OncoProg ® digital pathology computational software product OXFORD, UK – July 19th,
PRESS RELEASE: Kyoung Mee Lee joins our Board of Directors
Oxford Cancer Biomarkers Ltd is pleased to announce that Kyoung Mee Lee has joined our Board of Directors. OXFORD,
ColoProg becomes OncoProg
Oxford Cancer Biomarkers are pleased to announce the rebranding of our ColoProg ® product to OncoProg ® OXFORD, UK
ToxNav ® validation data published
Today, Oxford Cancer Biomarkers are pleased to announce the publication of the ToxNav ® clinical validation study in the journal
HAPB3 joins the ToxNav panel
The team at Oxford Cancer Biomarkers (OCB) are pleased to announce the expansion of our ToxNav® DPYD genomics panel with
Colorectal cancer in the Covid-19 era
Professors David and Rachel Kerr’s proposed colorectal cancer treatment guidelines for patients during the COVID-19 era. AIMS To reduce the